Basic Science and Pathogenesis.

Background: Longitudinal population-based studies have consistently revealed an expedited cognitive decline in the elderly population with type 2 diabetes mellitus (DM2). Additionally, there is a documented increased risk of developing vascular dementia and Alzheimer's disease in individuals with DM2. Conversely, recent research has pointed to metformin (MET), a widely prescribed medication for type 2 diabetes mellitus (T2DM), potentially mitigating age-related cognitive dysfunction (Madhu et al.